Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...

Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...